Samsung Biologics Secures Top ESG Rating From Morningstar Sustainalytics

Samsung Biologics, a leading contract development and manufacturing organization, has received a top ESG rating from Morningstar Sustainalytics. The company achieved a 'Negligible Risk' classification, which is the lowest risk category, reflecting its strong performance in environmental, social, and governance criteria.

The rating improved from a previous 'Low Risk' classification to a score of 9.0, placing Samsung Biologics among the top 0.5% of companies in the pharmaceutical industry evaluated by Sustainalytics. This independent research firm assesses around 16,000 companies globally for their exposure to ESG risks and their management of those risks.

John Rim, President and CEO of Samsung Biologics, emphasized the importance of effective risk management, stating, "This recognition demonstrates the progress we have made in embedding responsible practices across our business."

In addition to this latest recognition, Samsung Biologics also received an 'A' rating in the 2026 MSCI ESG Ratings assessment and the EcoVadis Platinum Sustainability Rating earlier this year, further solidifying its reputation in sustainability efforts.